Combined approach offers hope to lung cancer patients who become resistant to drugs

July 25, 2018, Weizmann Institute of Science
Response to treatment in cancer cells: The abundance of the EGFR (top row) and HER2 (bottom row) receptors is reduced when the cells are exposed to triple therapy -- Tagrisso, Erbitux and Herceptin (right column) and to the two antibodies, Erbitux and Herceptin (second from right column), but not when they are exposed to Tagrisso alone (second column from left) or to no therapy at all (left column): The abundance of the EGFR (top row) and HER2 (bottom row) receptors is reduced when the cells are exposed to triple therapy -- Tagrisso, Erbitux and Herceptin (right column) and to the two antibodies, Erbitux and Herceptin (second from right column), but not when they are exposed to Tagrisso alone (second column from left) or to no therapy at all (left column) Credit: Weizmann Institute of Science

New-generation lung cancer drugs have been effective in a large number of patients, but within about a year, the patients tend to develop resistance to the therapy. Researchers at the Weizmann Institute of Science, in collaboration with physicians, have conducted a study in mice, in which they used existing drugs in a new combination to help crush potential resistance to the treatment. Their findings were published recently in the journal Clinical Cancer Research.

Lung is the most common cause of death from malignancy, accounting for about one-fifth of cancer deaths worldwide according to World Health Organization estimates. New drugs treat certain subtypes of this cancer by targeting the genetic characteristic of each subtype.

In about 12%, on average, of patients—most of them non-smokers—the malignancy is due to a mutation in a gene called EGFR. This gene encodes a receptor that is embedded in the cell membrane, protruding in both directions: Its "head," the outer portion on the , binds with a growth factor that transmits a growth signal to the cell; the "legs," the inner portion inside the cell, works as an enzyme that further conveys the signal to the cellular nucleus. EGFR's growth message prompts the cell to divide which normally serves a good purpose—for example, helping tissues to heal—but a mutation on the inner part of the receptor can cause the cell to divide uncontrollably, leading to cancer.

Patients with the EGFR mutation can be helped by small molecules known as kinase inhibitors, which block the mutation, preventing EGFR from generating a signal for uncontrolled division. These drugs work much better than chemotherapy: They are more effective and cause fewer side effects, and they can be taken as a pill rather than by injection. The problem is that within 10 to 14 months many of the patients develop a secondary mutation in the EGFR. This causes their tumors to relapse because it enables EGFR to get around the kinase inhibitor

In 2015, a new known by the trade name Tagrisso, which blocks this second mutation, was approved for clinical use when the lung tumor starts growing again. Tagrisso helps, but usually not for long. Again, within 10 to 14 months a third mutation or other alterations emerge in the EGFR gene, causing another relapse.

"This of course is a nightmare for the patients, their families and the doctors," says Prof. Yosef Yarden of the Biological Regulation Department. "We've now developed a new approach that works in mice and may help relieve this frustrating situation if our method proves to work in humans."

In collaboration with physicians from the Chaim Sheba Medical Center in Tel Hashomer, Israel, Yarden's team tried out a . Mice implanted with human lung cancer were given Tagrisso and a drug that blocks the EGFR on the cell surface. This drug was Erbitux, an antibody that binds to the protruding outer portion of the EGFR, preventing the cell from receiving the growth message. The Tagrisso they were given works inside the cell, preventing the inner portion of EGFR, the growth-promoting kinase, from relaying the growth signal.

This original attempt at a combination therapy had proved unsuccessful, probably because when EGFR is blocked on the cell surface, it calls upon a close "relative," a receptor called HER2, to pop up on the cell membrane. So in the new study, the researchers gave mice a triple combination therapy, which apart from Tagrisso included two antibodies instead of one: Erbitux and a drug called Herceptin, which blocks HER2.

This time the approach worked. Tumors shrunk substantially and did not regrow as long as the mice received the triple combination treatment. The use of this approach in human should be facilitated by the fact that both antibodies are drugs already approved for use against other cancers: Erbitux is used in colorectal and Herceptin, in breast, cancer.

"If confirmed in humans, the new combination therapy may help extend the lives of many thousands of who currently develop resistance to kinase inhibitors," Yarden says.

Explore further: FDA approves new therapy option for lung cancer patients who develop resistance to early generation EGFR inhibitors

More information: Donatella Romaniello et al. A Combination Of Approved Antibodies Overcomes Resistance Of Lung Cancer To Osimertinib By Blocking Bypass Pathways, Clinical Cancer Research (2018). DOI: 10.1158/1078-0432.CCR-18-0450

Related Stories

FDA approves new therapy option for lung cancer patients who develop resistance to early generation EGFR inhibitors

November 16, 2015
The International Association for the Study of Lung Cancer (IASLC) commends the U.S. Food and Drug Administration's (FDA) decision to grant accelerated approval for osimertinib (Tagrisso), an oral medication for advanced ...

Triple treatment keeps cancer from coming back

June 3, 2015
Lung cancer is the leading cause of cancer death worldwide, responsible for some 1.59 million deaths a year. That figure is due, in part, to the fact that the cancer often returns after what, at first, seems to be successful ...

Scientists reveal that new combination of clinically tested drugs inhibits growth of lung tumors

September 8, 2017
Research at the University of Southern Denmark has revealed that a new combination of clinically tested drugs inhibits the growth of tumours, thereby potentially improving patients' survival.

Researchers report a new target to treat prostate cancer

December 22, 2017
The drug Gefitinib is used to treat breast, lung, and other cancers by inhibiting epidermal growth factor receptor (EGFR) signaling, but it has only a limited effect on prostate cancer. EGFR, present on the cell membrane, ...

Not all EGFR mutations are the same when it comes to therapy for non-small cell lung cancer

February 10, 2015
Certain rare epidermal growth factor receptor (EGFR) mutations are associated with tobacco smoking, worse prognosis and poor response to EGFR tyrosine kinase inhibitor (TKI) therapy compared to the more common "classical" ...

Study finds breast cancer driver, HER2, in 3 percent of lung cancers

July 27, 2017
The Lung Cancer Mutation Consortium at the University of Colorado Cancer Center reports this week in the journal Cancer that 24 of 920 patients (3 percent) with advanced-stage lung cancer had mutations in the gene HER2. Seventy-one ...

Recommended for you

Healthy diets linked to better outcomes in colorectal cancer

October 20, 2018
Colorectal cancer patients who followed healthy diets had a lower risk of death from colorectal cancer and all causes, even those who improved their diets after being diagnosed, according to a new American Cancer Society ...

Scientists to improve cancer treatment effectiveness

October 19, 2018
Together with researchers from the University of Nantes and the University of Reims Champagne-Ardenne in France, experts from the National Research Nuclear University MEPhI have recently developed a quantum dot-based microarray ...

Why some cancers affect only young women

October 19, 2018
Among several forms of pancreatic cancer, one of them specifically affects women, often young. How is this possible, even though the pancreas is an organ with little exposure to sex hormones? This pancreatic cancer, known ...

Mutant cells colonize our tissues over our lifetime

October 18, 2018
By the time we reach middle age, more than half of the oesophagus in healthy people has been taken over by cells carrying mutations in cancer genes, scientists have uncovered. By studying normal oesophagus tissue, scientists ...

Study involving hundreds of patient samples may reveal new treatment options of leukemia

October 17, 2018
After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, "Functional Genomic Landscape of Acute Myeloid Leukemia", published ...

A 150-year-old drug might improve radiation therapy for cancer

October 17, 2018
A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation therapy, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.